Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 (as Monotherapy or in Combination With Pembrolizumab) in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235 is registered in ClinicalTrials.gov with Flare Therapeutics Inc. as lead sponsor.

NCT NCT05929235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05929235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 (as Monotherapy or in Combination With Pembrolizumab) in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Lead sponsor
Flare Therapeutics Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 24, 2023
Completion date
January 30, 2028
Enrollment
120 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced urothelial carcinoma, open label, oral drug administration